Phase II/III pivotal study of Cannabidiol in Fragile-X-syndrome.
Phase of Trial: Phase II/III
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Cannabidiol (Primary)
- Indications Fragile X syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Zynerba Pharmaceuticals
- 05 Mar 2018 According to a Zynerba Pharmaceuticals media release, this trial will support a New Drug Application (NDA) for ZYN002 in Fragile-X-syndrome.
- 09 Jan 2018 New trial record
- 03 Jan 2018 According to the Zynerba Pharmaceuticals media release, data read out from this study is expected in 2019.